Bresnahan, Rebecca http://orcid.org/0000-0001-5578-1535
Houten, Rachel http://orcid.org/0000-0002-4315-7732
Greenhalgh, Janette http://orcid.org/0000-0003-4812-1904
Nevitt, Sarah http://orcid.org/0000-0001-9988-2709
Mahon, James http://orcid.org/0000-0002-2187-1003
Beale, Sophie http://orcid.org/0000-0003-0164-103X
Boland, Angela http://orcid.org/0000-0002-5435-8644
Bhattacharyya, Devarshi http://orcid.org/0000-0003-1694-8106
Dundar, Yenal http://orcid.org/0000-0002-9847-1622
McEntee, Joanne
Gandhi, Shreyans
Fleeman, Nigel http://orcid.org/0000-0002-4637-9779
Chaplin, Marty http://orcid.org/0000-0002-7097-8704
Funding for this research was provided by:
Evidence Synthesis Programme (NIHR133733)
Article History
Accepted: 8 March 2023
First Online: 17 May 2023
Declarations
:
: This project was funded by the National Institute for Health Research Evidence Synthesis Programme as project number NIHR133733. See the Evidence Synthesis Programme website for further project information. ExternalRef removed. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the National Institute for Health and Care Excellence or the Department of Health.
: The authors have no competing interests. This article was not externally peer reviewed by <i>PharmacoEconomics—Open</i>.
: Not applicable.
: Not applicable.
: Not applicable.
: Additional data and material relevant to this appraisal are available on the NICE webpage: ExternalRef removed. Data are subject to third party restrictions. In the data sharing statement for Hillmen et al. 2021 [CitationRef removed] (the primary study publication for the PEGASUS trial), the company state that “access to patient-level data with qualified external researchers may be available upon request and review once the trial is complete and data are published”.
: Not applicable.
: Rebecca Bresnahan: Project lead and critical appraisal of the clinical evidence. Rachel Houten: Critical appraisal of the economic evidence. Janette Greenhalgh: Critical appraisal of the clinical evidence. Sarah Nevitt: Critical appraisal of the statistical evidence. James Mahon: Critical appraisal of the economic evidence. Sophie Beale: Critical appraisal of the clinical and economic evidence and editorial input. Angela Boland: Critical appraisal of the clinical and economic evidence and editorial input. Devarshi Bhattacharyya: Critical appraisal of the economic evidence. Yenal Dundar: Critical appraisal of the clinical evidence, including search strategies. Joanne McEntee: Critical appraisal of the company submission. Gandhi Shreyans: Critical appraisal of the company submission. Nigel Fleeman: Editorial input. Marty Chaplin: Editorial input. All authors read and commented on draft versions of this paper.